Genmab pipeline hype makes investment bank uneasy
![Photo: Lars Møller / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13436342.ece/ALTERNATES/schema-16_9/doc7i9xkcm6vhh109nhgdxa.jpg)
Although Genmab has been called a "superstar" and "one of the best European biotech companies," Berenberg Bank has changed its recommendation to "sell", with a target price of DKK 2,200 (USD 334).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Anthony Mancini will help Genmab take its next steps
For subscribers